Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.76 |
| ▸ | GLP1R | P43220 | 8/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.65 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.62 |
| ▸ | CASP2 | P42575 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25542989 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL25542969 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL13855525 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL25542983 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL7041680 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL13855526 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL14937066 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL14937349 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL14937344 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 | |
| SCHEMBL25542900 | 1.00 | NOD1 (0.76) | NOD1GLP1REPHX2SLC6A5CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1065212-A2 | Lipopeptide inducing T-cytotoxic lymphocytes and their use as vaccines | INSTITUT PASTEUR DE LILLE (FR) | 2001-01-03 | — | — | EP | claimed |
| US-5993823-A | BETWEEN 10 AND 40 AMINO ACIDS AND AT LEAST ONE ANTIGENIC DETERMINANT, ALSO COMPRISING A CHAIN FROM PIMELAUTIDE, TRIMEXAUTIDE, HEXADECANOIC ACID, 2-AMINO-HEXADECANOIC ACID, STEROID GROUPS AND DERIVATIVES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 1999-11-30 | — | — | US | claimed |
| EP-0491628-B1 | Lipopeptide inducing T-cytotoxic lymphocytes and their use as vaccines | PASTEUR INSTITUT (FR) | 1999-09-29 | — | — | EP | claimed |
| EP-0491628-A2 | Lipopeptide inducing T-cytotoxic lymphocytes and their use as vaccines | INSTITUT PASTEUR DE LILLE (FR) | 1992-06-24 | — | — | EP | claimed |
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
| EP-1930409-B1 | L-GLUTAMIC ACID-PRODUCING BACTERIUM AND METHOD FOR PRODUCTION OF L-GLUTAMIC ACID | AJINOMOTO KK (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-7867735-B2 | L-glutamic acid producing bacterium and a method for production of L-glutamic acid | AJINOMOTO CO., INC. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20090258402-A1 | L-Glutamic Acid Producing Bacterium and a Method for Production of L-Glutamic Acid | AJINOMOTO CO., INC. (JP) | 2009-10-15 | — | — | US | disclosed |
| EP-1930409-A1 | L-GLUTAMIC ACID-PRODUCING BACTERIUM AND METHOD FOR PRODUCTION OF L-GLUTAMIC ACID | Ajinomoto Co., Inc. (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1293560-B1 | Methods for producing L-lysine and L-glutamic acid by fermentation | AJINOMOTO KK (JP) | 2007-11-14 | — | — | EP | disclosed |
| EP-0780477-B1 | PROCESS FOR PRODUCING L-LYSINE AND L-GLUTAMIC ACID BY FERMENTATION | AJINOMOTO KK (JP) | 2003-04-09 | — | — | EP | disclosed |
| EP-1293560-A2 | Methods for producing L-lysine and L-glutamic acid by fermentation | Ajinomoto Co., Inc. (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-5871746-A | FOR IMMUNIZING AGAINST PATHOGENIC AGENTS SUCH AS VIRUSES ORPARASITES; ONE OR MORE CHAINS DERIVED FROM FATTY ACIDS OR MODIFIED STEROID GROUPS | INSTITUT NATIONAL DE LA SAINTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1999-02-16 | — | — | US | disclosed |
| US-5846790-A | Methods of producing L-lysine and L-glutamic acid by fermentation | AJINOMOTO CO., INC. (JP) | 1998-12-08 | — | — | US | disclosed |
| EP-0780477-A1 | PROCESS FOR PRODUCING L-LYSINE AND L-GLUTAMIC ACID BY FERMENTATION | Ajinomoto Co., Inc. (JP) | 1997-06-25 | — | — | EP | disclosed |
| US-4868155-A | IMMUNE SYSTEM STIMULANTS | MERCK & CO., INC. (US) | 1989-09-19 | — | — | US | disclosed |
| US-4442090-A | ACYLATED AMINO ACID | KYOTO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1984-04-10 | — | — | US | disclosed |
| US-4368190-A | IMMUNOADJUVANT | MERCK & CO., INC. (US) | 1983-01-11 | — | — | US | disclosed |
| EP-0038750-A1 | Immunologically active dipeptidyl 4-0-, 6-0-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation | MERCK & CO. INC. (US) | 1981-10-28 | — | — | EP | disclosed |
| US-3971701-A | FATTY ACID, ESTER OR N-ACYLAMINO ACID SURFACTANT | AJINOMOTO CO., INC. (JA) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | NOD1 1668/4885GLP1R 1506/4885EPHX2 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.